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OBJECTIVES We sought to evaluate the frequency of pulmonary congestion and associated clinical and
hemodynamic findings in patients with suspected cardiogenic shock (CS).
BACKGROUND The prevalence of pulmonary congestion in the setting of CS is uncertain.
METHODS The 571 SHOCK Trial Registry patients with predominant left ventricular failure (LVF)
were divided into four groups: Group A 5 no pulmonary congestion/no hypoperfusion 5 14
(3%), Group B 5 isolated pulmonary congestion 5 32 (6%), Group C 5 isolated
hypoperfusion 5 158 (28%) and Group D 5 congestion with hypoperfusion 5 367 (64%).
Statistical comparisons between Group C and D only, with regard to patient demographics,
hemodynamics, treatment and outcome, were made.
RESULTS A significant proportion of patients with shock had no pulmonary congestion (Group C 5
28%, 95% CI, 24% to 31%). Age and gender in this group were similar to Group D. Group
C patients were less likely to have a prior MI (p 5 0.028), congestive heart failure (p 5 0.005)
and renal insufficiency (p 5 0.032), and the index MI was less likely to be anterior (p 5
0.044). Cardiac output, cardiac index and ejection fraction were similar for the two groups but
pulmonary capillary wedge pressure was slightly lower for Group C (22 vs. 24 mm Hg, p 5
0.012). Treatment with thrombolysis, angioplasty and bypass surgery was similar in the two
groups. In-hospital mortality rates for Groups C and D were 70% and 60%, respectively (p 5
0.036). After adjustment, this difference was no longer statistically significant (p 5 0.153).
CONCLUSIONS Absence of pulmonary congestion at initial clinical evaluation does not exclude a diagnosis of
CS due to predominant LVF and is not associated with a better prognosis. (J Am Coll
Cardiol 2000;36:1071–6) © 2000 by the American College of Cardiology
A critical loss of functional left ventricular (LV) myocar-
dium in the setting of acute myocardial infarction (AMI)
may result in cardiogenic shock (CS) (1–3). Cardiogenic
shock is the leading cause of in-hospital death following
AMI in both thrombolytic and non-thrombolytic treated
populations (4). Unfortunately, patients with CS have been
excluded (5) from randomized clinical trials, albeit with a
few notable exceptions (6–10). Furthermore, hemodynamic
confirmation has been lacking in a large proportion of study
patients. As a result, clinical and hemodynamic presentation
with this clinical entity remains diverse and poorly defined.
The purpose of this article is to report on the prevalence of
pulmonary congestion (PC) at shock onset and to correlate
hemodynamic and clinical findings at shock presentation.
The SHould we emergently revascularize Occluded Cor-
onaries in cardiogenic shocK? (SHOCK) Trial was a large
prospective randomized study of CS complicating AMI
(11). The study completed enrollment in November 1998
and the results of the randomized Trial have been published
(12). Criteria for the randomized study were stringent and
trial-ineligible and trial-eligible but non-consenting patients
with clinical CS were prospectively enrolled in the SHOCK
Trial Registry. Patients in this Registry form the subject of
this report.
METHODS
Patient selection. A detailed description of the SHOCK
Trial Registry methodology is reported by Hochman et al.
(11,13). Registry patients with suspected CS due to pre-
dominant left ventricular failure (LVF) are the subject of
these analyses. Initial case report forms did not include data
for PC. Consequently, of the 884 patients with predomi-
nant LVF, 313 patients were excluded due to absence of
data. In subsequent forms, these clinical findings were
assessed on the basis of clinical evaluation performed at the
time of initial evaluation for CS and 571 patients in the
SHOCK Trial Registry had sufficient data for further
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analysis. Four clinical groups were analyzed based on pre-
specified definitions for oliguria, peripheral hypoperfusion
and PC (see following text): Group A 5 no evidence of
clinical hypoperfusion or PC; Group B 5 PC but no
evidence of clinical hypoperfusion; Group C 5 clinical
hypoperfusion but no PC at radiographic or physical exam-
ination; and Group D 5 clinical hypoperfusion and PC. Of
the 571 patients, 353 underwent right heart catheterization
(RHC) as part of their in-hospital management. Hemody-
namic data, treatment and clinical outcomes are reported for
each of these subsets.
Definitions. Cardiogenic shock was defined as sustained
hypotension (systolic blood pressure (BP) ,90 mm Hg
lasting .30 min) accompanied by evidence of tissue hypo-
perfusion in the setting of clinically adequate or elevated LV
filling pressures. Predominant LVF was defined as the
etiology of CS when none of the following shock categories
was indicated: right ventricular (RV) infarction causing CS,
acute severe mitral regurgitation, ventricular septal rupture,
LV rupture and prior severe valvular heart disease or
iatrogenic shock. Peripheral hypoperfusion was defined as
the presence of cold peripheries, oliguria ,30 ml/h, or both.
The finding of cold peripheries was subjective and sup-
ported by physical findings of lower temperature in extrem-
ities compared with central temperature and associated
cyanosis. Pulmonary congestion was defined as the presence
of rales at pulmonary examination or a radiographic report
of pulmonary alveolar/interstitial congestion at initial chest
roentgenogram.
Statistical analysis. All continuous variables are presented
as mean 6 standard deviation. A two-sided p value ,0.05
was considered statistically significant. Only descriptive
statistics are provided for Groups A and B due to 1) their
lack of a clear shock diagnosis (i.e., no hypoperfusion) and
2) their consequent small sample size. Statistical compari-
sons of Groups C and D only were made. The Fisher exact
test was used for comparison of discrete variables, and a
t-test or Wilcoxon test was used for continuous variables.
Logistic regression was used to model the association
between in-hospital mortality and clinical group (C vs. D).
All patient and treatment variables that were applicable to
the entire sample and had a Group C versus Group D
univariate p value of #0.20 were evaluated for inclusion in
a multivariate model for mortality. All analyses were con-
ducted using the Statistical Analysis System (SAS for
Windows, version 6.12.; SAS Institute, Cary, North Caro-
lina).
RESULTS
Demographics. Group A consisted of 14 (3%) patients;
Group B had 32 (6%); Group C had 158 patients (28%);
and Group D had 367 (64%). Table 1 illustrates the profile
of the patients in the four clinical groups. Although Groups
C and D were comparable with respect to age and gender,
patients in Group C were less likely to have had a previous
MI, congestive heart failure, renal insufficiency and index
anterior wall AMI. The time from AMI to onset of CS was
also similar in both groups.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
BP 5 blood pressure
CS 5 cardiogenic shock
ECG 5 electrocardiogram, electrocardiographic
LVF 5 left ventricular failure
PC 5 pulmonary congestion
PCWP 5 pulmonary capillary wedge pressure
RHC 5 right heart catheterization
RV 5 right ventricular, right ventricle
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries in cardiogenic shocK?
Table 1. Profile of Patients With Predominant LV Failure in the SHOCK Trial Registry
Group A Group B Group C Group D p Value*
n 14 32 158 367
Age (yrs) 59.4 6 11.1 65.8 6 11.1 68.8 6 12.1 69.6 6 11.4 0.513
Male 64.3% 53.1% 59.5% 65.1% 0.236
History of hypertension 50.0% 53.1% 51.0% 54.2% 0.555
Diabetes 7.1% 32.3% 28.5% 34.9% 0.180
History of congestive heart failure 0.0% 9.7% 12.3% 23.8% 0.005
History of renal insufficiency 0.0% 6.7% 7.1% 14.2% 0.032
Smoking 64.3% 54.8% 55.5% 54.2% 0.832
History of elevated cholesterol 38.5% 38.5% 37.8% 42.5% 0.420
History of peripheral vascular disease 0.0% 19.4% 18.6% 19.4% 0.898
History of MI 28.6% 32.3% 34.3% 45.3% 0.028
History of bypass surgery 14.3% 12.5% 15.2% 9.2% 0.061
History of angioplasty 7.1% 9.7% 6.7% 6.9% 1.000
Index anterior MI 69.2% 69.0% 49.7% 59.8% 0.044
Highest creatine kinase† 3865 2679 1904 1532 0.955
MI—shock (median hours) 15.3 10.3 4.4 6.3 0.094
*Group C vs. Group D; † 5 median value.
Group A 5 No congestion/no hypoperfusion; Group B 5 Isolated pulmonary congestion; Group C 5 Isolated
hypoperfusion; Group D 5 Hypoperfusion with pulmonary congestion.
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Hemodynamic data. Right heart catheterization was per-
formed in 11 of 14 patients (79%) in Group A, in 29 of 32
(91%) in Group B, in 89 of 159 (56%) in Group C and in
224 of 367 (61%) in Group D. The hemodynamic findings
at the time of RHC for suspected clinical CS are presented
in Table 2. Groups C and D meet standard criteria for CS
Figure 1. This figure plots PCWP against cardiac index for individual patients in Group C (isolated hypoperfusion). Because a majority of patients in this
group have PCWP .15 mm Hg, occult predominant RV dysfunction in the setting of inferior infarction does not appear to play a major role in this clinical
presentation.
Table 2. Hemodynamics for Patients With Predominant LV Failure in the SHOCK Trial Registry
Group A Group B Group C Group D p Value*
Heart rate 92.4 6 18.2 (14) 101.8 6 22.6 (31) 91.1 6 27.1 (147) 96.1 6 25.8 (351) 0.052
SBP in mm Hg 95.6 6 13.8 (14) 102.2 6 20.8 (31) 84.9 6 25.5 (147) 88.0 6 24.1 (357) 0.193
DPB in mm Hg 56.9 6 19.4 (14) 58.3 6 11.9 (30) 51.1 6 19.3 (135) 51.8 6 17.7 (311) 0.718
Lowest SBP in mm Hg 72.4 6 11.7 (14) 51.6 6 37.6 (32) 61.4 6 25.6 (158) 67.5 6 20.0 (367) 0.003
RHC 11 29 89 224
RAP in mm Hg 13.1 6 6.3 (8) 11.9 6 7.1 (20) 14.6 6 5.9 (60) 14.6 6 8.4 (158) 0.481
PAS in mm Hg 38.4 6 8.0 (9) 40.9 6 14.4 (25) 38.5 6 12.4 (80) 42.3 6 13.0 (192) 0.008
PAD in mm Hg 23.2 6 5.1 (9) 24.5 6 7.9 (26) 22.3 6 8.2 (80) 24.3 6 8.9 (194) 0.015
PCWP in mm Hg 22.7 6 7.8 (11) 21.9 6 9.8 (29) 21.5 6 6.7 (82) 24.3 6 8.1 (209) 0.012
SVR in dynes/sec/cm25 1632 6 853 (4) 1597 6 579 (15) 1556 6 702 (43) 1454 6 693 (119) 0.538
Cardiac index in 1/min/m2 2.1 6 0.8 (7) 2.3 6 1.0 (21) 1.9 6 0.6 (62) 2.1 6 0.8 (170) 0.218
Cardiac output in 1/min 4.2 6 2.2 (6) 4.0 6 1.4 (20) 3.6 6 1.3 (62) 3.9 6 1.7 (168) 0.418
In-hospital LVEF in % 37.8 6 16.2 (9) 27.8 6 9.8 (20) 30.9 6 12.5 (66) 30.4 6 12.8 (202) 0.839
*Group C vs. Group D.
Group A 5 No congestion/no hypoperfusion, Group B 5 Isolated pulmonary congestion, Group C 5 Isolated hypoperfusion, and Group D 5 Hypoperfusion with
pulmonary congestion.
( ) 5 number of patients with data.
SBP 5 systolic blood pressure, DBP 5 diastolic blood pressure, LVEF 5 left ventricular ejection fraction, PCWP 5 pulmonary capillary wedge pressure, RAP 5 right atrial
pressure and RHC 5 right heart catheterization, SVR 5 systemic vascular resistance.
Values were often recorded while the patient was on hemodynamic support.
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with hypotension, elevated pulmonary capillary wedge pres-
sure (PCWP) and depressed cardiac index #2.2. Although
the mean cardiac indexes in these groups are comparable,
Group C patients had a significantly lower mean PCWP
(22 6 7 vs. 24 6 9 mm Hg, p 5 0.012) as well as lower
pulmonary systolic and diastolic pressures. Other parame-
ters, including heart rate, systolic BP, diastolic BP, right
atrial pressure, systemic vascular resistance and cardiac
output were comparable for Groups C and D. In-hospital
LV ejection fraction was also similar in Groups C and D.
Figure 1 plots PCWP against cardiac index for patients in
Group C. Although this Group C has more index non-
anterior MI, occult predominant RV dysfunction and vol-
ume depletion appear not to play a major role in this subset.
As illustrated, a majority of patients in this group have
PCWP .15 mm Hg.
Management. Almost one-third of the patients in both
Groups C and D were treated with thrombolysis (Table 3).
The rates of diagnostic coronary angiography, percutaneous
angioplasty and bypass surgery, hemodynamic support with
intra-aortic balloon pump counterpulsation and use of
mechanical ventilation were comparable for Groups C and
D. The overwhelming majority of patients in both groups
required intravenous vasopressors as part of their medical
care. However, intravenous inotropes were used less often in
Group C, compared with D (60% vs. 77%, p , 0.001).
Angiography. Coronary angiography was performed on 96
patients (61%) in Group C and 233 (63%) patients in
Group D. Patients in Group C had more single-vessel
disease (27.5% vs. 14.6%) and less triple-vessel disease
(49.5% vs. 63.5%) (p 5 0.002). The distribution of left main
disease in both clinical groups was comparable (16% vs.
19%, p 5 0.624).
In-hospital mortality. In-hospital mortality rates for
Groups A and B were 21% and 22%, respectively. The
outcome of Groups C and D were poor, with in-hospital
mortality of 70% and 60%, respectively (odds ratio [OR] for
death 1.53, 95% confidence interval [CI] 1.03 to 2.28, p 5
0.036; n 5 525). After adjusting for prior MI, lowest
recorded systolic BP, and inotrope administration, there was
no significant difference in mortality for Groups C and D
(OR for death 1.38, 95% CI 0.89 to 2.13, p 5 0.153, n 5
476).
DISCUSSION
In this large, prospective, international Registry of suspected
CS complicating AMI we observed that the majority of
patients with predominant LVF causing CS have classical
findings of peripheral hypoperfusion and PC (Group D) in
the setting of arterial hypotension. It is, however, remark-
able that in the setting of severe acute LV dysfunction,
approximately one-quarter of patients manifest hypotension
and hypoperfusion in the absence of clinical PC (Group C).
Unadjusted in-hospital mortality was higher in this group
than that observed for patients with PC in conjunction with
peripheral hypoperfusion.
The absence of PC in the presence of an elevated PCWP
has been previously documented (14). Its prevalence in the
setting of acute LVF complicating AMI, however, deserves
emphasis. Our observations suggest that this is not an
uncommon phenomenon. Consequently, the absence of PC
at physical evaluation should not be considered a surrogate
for low risk. Clearly, LV compromise can coexist with a
normal initial pulmonary evaluation.
Pathogenesis and outcome. The absence of PC in the
setting of AMI and elevated PCWP appears multi-factorial.
Although an increase in PCWP likely reflects increased LV
volume (15), a number of factors may modify its degree and
rate of rise. The PCWP may be greatly influenced by the
functional capacity of the lymphatics as well as variations in
interstitial, oncotic and hydrostatic pressure (16). The
highly variable diastolic stiffness of the left ventricle and the
impact of positive ventilation may also contribute to a
heterogeneous response (17,18). The administration of
vasopressor and vasodilator therapy and the difficulty in
accurately examining the ventilated supine critically ill
patient in the modern intensive care unit may also contrib-
ute to this observation.
It is unlikely that isolated RV infarction secondary to
inferior myocardial infarction explains the findings observed
in Group C. Patients diagnosed with CS secondary to RV
Table 3. Treatment of Patients With Predominant LV Failure in the SHOCK
Trial Registry
Group A Group B Group C Group D p Value*
n 14 32 158 367
Thrombolytic (%) 14.3 43.8 31.7 31.7 1.000
Coronary angiography (%) 85.7 75.0 60.8 63.5 0.557
Angioplasty (%) 64.3 37.5 35.4 30.0 0.221
Bypass surgery (%) 21.4 9.4 12.7 16.9 0.240
IABP (%) 64.3 53.1 52.5 52.9 1.000
Ventilator (%) 64.3 65.6 73.4 77.7 0.314
Intravenous vasopressor use (%) 78.6 93.8 95.6 96.7 0.611
Intravenous inotrope use (%) 57.1 75.0 60.1 76.8 , 0.001
*Group C vs. Group D.
Group A 5 No congestion/no hypoperfusion, Group B 5 Isolated pulmonary congestion, Group C 5 Isolated
hypoperfusion, and Group D 5 Hypoperfusion with pulmonary congestion.
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infarction were not considered for this analysis and are
reported elsewhere (19). Only 5 of 82 (6%) patients with
isolated hypoperfusion in Group C had a PCWP ,12mm
Hg. Further, mean right atrial pressure in Group C was
similar to Group D. Left ventricular ejection fraction was
similar and the PCWP was only marginally lower.
Readers should note that our patients differ from the
classical description of isolated hypoperfusion resulting from
RV involvement complicating inferior wall myocardial in-
farction (20). Patients with isolated hypoperfusion in these
reports were chosen from the entire universe of AMI and
were found to have normal to low PCWP and increased
right atrial pressure secondary to hemodynamically signifi-
cant RV infarction (20). By contrast, our patients with
isolated hypoperfusion were selected for predominant LVF
and have a mean PCWP of 22 6 7 mm Hg and ejection
fraction of 30%. Thus, although patients with hypotension
secondary to RV infarction “respond in a hemodynamically
beneficial manner to volume replacement” (20), the re-
sponse to a volume bolus in our population with isolated
hypoperfusion is uncertain and unreported. Although vol-
ume infusion may potentially harm some patients with very
elevated PCWP, a potential benefit of moderate volume
infusion for these patients cannot be ruled out, because
volume administration may result in a rise in both PCWP
and cardiac index. In the presence of a large infarction on
surface ECG, echo documentation of RV and LV function
are worthwhile before administering a significant fluid
challenge.
The high mortality rates observed in Groups C and D are
not surprising. Hemodynamic data, including cardiac out-
put and PCWP were shown to be the strongest predictors of
death in the Global Utilization of Streptokinase and tPA for
Occluded Coronary Arteries (GUSTO) CS mortality model
(21). Equally relevant is the fact that the physical findings of
oliguria and cold peripheries were each independent and
strongly predictive of mortality in this clinical setting (21,
22). These physical findings correlated more strongly with
death than low BP. Both study Groups C and D have a low
cardiac index in the setting of peripheral hypoperfusion—a
harbinger of in-hospital death.
Previous studies. Elegant work performed in the past has
validated the utility of the clinical examination in risk
stratifying patients with AMI (20,23,24). Major limitations
of the clinical prediction of the hemodynamic state have also
been identified (20). These include the under-diagnosis of
depressed cardiac index in 14% of patients and the failure to
recognize an elevated wedge in about 15% of patients. The
original report by Killip et al. (23) highlighted PC as a
component of CS. Our experience shows that patients with
clear lungs may be nevertheless in florid CS.
Study limitations. The use of RHC was not mandated by
protocol, and the decision to place a RHC was local and
investigator-dependent. Despite similar clinical findings,
hemodynamics in those receiving and not receiving RHC
may have been different. Although it is performed in tertiary
critical care units, the accuracy of the measurements ob-
tained with RHC cannot be verified by an independent
investigator. The use of diuretic therapy prior to shock
assessment was not recorded in the SHOCK Trial Registry,
and the use of vasodilators (specifically, IV nitroglycerin)
was not documented. These agents may have had a signif-
icant role in decreasing preload and mitigating PC. How-
ever the high PCWP and the similar right atrial pressures
suggest that this did not significantly influence our findings.
Patients enrolled in the SHOCK Trial Registry were not
randomized to defined treatment strategies. Although the
study groups appear adequately matched, a number of
unrecorded variables may have influenced the subsequent
outcome. There was no core laboratory for chest roentgen-
ograms, and we acknowledge that the accuracy of physical
findings is limited by clinical experience and subject to
interobserver variability.
Conclusions. Right heart catheter utilization has declined
in the setting of CS (25). The potential harm attributed to
the RHC in the critical care setting may have contributed to
this observation (26). This decline in invasive hemodynamic
monitoring has important implications regarding the em-
piric administration of large intravenous fluid challenges to
patients with large infarctions who present with hypoten-
sion and hypoperfusion. Non-invasive assessment of ven-
tricular function is strongly advocated for patients with
suspected CS.
Clinicians must be aware that PC may be absent when
CS complicates AMI. Clinical hypoperfusion in the setting
of AMI complicated by CS is a marker of in-hospital
mortality irrespective of the presence or absence of PC.
Early clinical recognition and triage of this group is clearly
warranted and may have an impact on outcome.
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